J.P. Morgan Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
In a report released on March 28, Yang Huang from J.P. Morgan maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a ...
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Medindia3d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
Nasdaq3d
Innovent Biologics Gets NMPA Breakthrough Therapy Designation For IBI363 In Melanoma
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy ...
Yahoo Finance3d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Pharmabiz2d
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma: San Francisco, US Tuesday, April 1, 202 ...